MedTrace Logo

Study of Alwextin® Cream in Treating Epidermolysis Bullosa

NCT00825565 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2018-02-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine how safe and effective allantoin 3% cream (Alwextin) is in improving the healing of recurrent skin lesions and reducing overall blistering in people with epidermolysis bullosa (EB). Allantoin 3% cream is applied topically to the entire body once daily.

Conditions

  • Epidermolysis Bullosa

Interventions

DRUG

Alwextin cream

Alwextin cream contains active ingredient, allantoin 3%. Use 1 application daily for 3 month duration.

Sponsors & Collaborators

Principal Investigators

  • Amy S Paller, MD · Northwestern University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00825565 on ClinicalTrials.gov